Navigation Links
World Anticoagulants Market to Exceed $12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Driven by patent expiries, development of novel therapeutics, and the rapidly aging population, the world market for anticoagulants is projected to exceed $12 billion by 2015. With just two therapy classes - vitamin K antagonist and heparin injectables, dominating the market, there exist enormous opportunities and interest in developing advanced, patient friendly anticoagulants.

San Jose, CA (PRWEB) October 30, 2008 -- The unmet medical needs of available anticoagulants offer ample scope for development in the world anticoagulants market. Continuous research and development is expected to result in novel therapies with superior therapeutic efficiency, and minimum side effects. These advanced therapeutics offer promising market prospects. Exanta, for instance, represents a cutting edge direct thrombin inhibitor that flaunts the potential to kindle demand patterns, dethrone warfarin's dominance, and challenge the supremacy of low molecular weight heparins. Identification of new indications for existing, and emerging therapies is expected to help open up brighter prospects for further growth.

Factor Xa inhibitors (oral and injectable) and direct thrombin inhibitors (oral and injectable) are among the new class of thrombin antagonists that are being evaluated for both existing as well as newer indications. Development of products for specific market niches, like, anticoagulation therapies for ischemic stroke, is additionally expected to result in expanded opportunities. Patent expiries of drugs like "Coumadin" offer a lucrative business case for generic drug manufacturers. Favorable demographic patterns, like the rapidly aging world population is expected to drive demand patterns, given the tendency of aging individuals to develop various venous and arterial complications.

The United States dominates the world anticoagulants market, with a share of nearly 50%, as stated by Global Industry Analysts, Inc. Strong double digit growth is expected to stem from the injectable anticoagulants market, with the United States setting the pace of growth with projected CAGR in excess of 15.1% over the period of 2000 through 2010. Market for injectable anticoagulants is dominated by low molecular weight heparin (LMWH). Strong growth in LMWH market is expected to push sales of injectable anticoagulants to US$6.6 billion by 2010. Japanese oral anticoagulants market is estimated to be worth US$38.3 million. In Europe, France represents the largest market with a 23.8% share.

Major market participants profiled include AstraZeneca PLC, Barr Laboratories Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi-Aventis.

The report titled "Anticoagulants: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, drivers, issues, challenges, and research and development activities. Richly annotated with authoritative, and unbiased commentaries, and hard-to-find statistical facts, the report provides unequivocal views on future potential while throwing light on the prevailing climate in key regional markets. Product markets analyzed in the report include Oral, and Injectable (Unfractionated Heparin, and Low Molecular Weight Heparin). Latent demand patterns in product markets are quantified across major geographic market verticals including the United States, Japan, France, Germany, United Kingdom, Italy, and Spain, among others for the period 2000-2015. Also provided in the report is an enumeration of recent mergers, acquisitions, and other strategic industry activities.

For more details about this research report, please visit

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Repair and healing of osteoporotic fractures a focus of upcoming IOF World Congress on Osteoporosis
2. Considering Revision Surgery? Board Certified Plastic Surgeon and Washington DC-based Dr. Mark E. Richards Pioneers Facelift Revisions Attracting Patients Worldwide
3. WorldHeart Announces Effectiveness of Reverse Stock Split
4. Our cheatin brain: The brains clever way of showing us the world as a whole
5. Several US Children Among Worldwide Heroes for Inspirational Fundraising Efforts with Celine Dion
6. World Biochips Market to Reach $3.4 billion by 2012, According to New Report by Global Industry Analysts, Inc.
7. University Of Minnesota Gives 11,538 Flu Shots Tuesday, Shattering Guinness World Record for Most Flu Shots in a Single Day
8. National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day
9. The Wireless World: Untethered Opportunities
10. This Holiday Season, Give a Gift that Does a World of Good
11. HTH Worldwide Unveils First Digital Healthcare Card
Post Your Comments:
Related Image:
World Anticoagulants Market to Exceed $12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds ... critical that the first impression be positive and reflects business values. If a client ... anything or want to return. They will also share their thoughts about a business ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin ... System. Brillouin is the developer of renewable energy technologies capable of producing commercially ... (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor core modules ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... is pleased to welcome Winter-Dent & Company as its newest Partner Firm. Based ... to become a client's most trusted advisor regardless of whether that client is ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the United States to support their local poison centers through donations on Tuesday, ... #GivingTuesday: calls it “a day that inspires people to collaborate in improving ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a ... of recent video interviews with some of the staff members at their recovery center. ... treatment facility, as well as some of the things that make their recovery program ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... NEWS, Va. , Nov. 24, 2015  DILON ... they have signed an agreement for DILON to distribute ... geographies across the globe. The signing of this distribution agreement ... Discovery NM750b Molecular Breast Imaging system and is considered ... to provide better healthcare solutions for clinicians and their ...
(Date:11/24/2015)... , Nov. 24, 2015 Avery Biomedical ... is pleased to announce the appointment of Anders ... Dr. Jonzon ... cardiology at Children,s Hospital, Uppsala University, Uppsala and Children,s ... 1984-1986, he was a fellow at the Cardiovascular Institute ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
Breaking Medicine Technology: